Our purpose is to drive change to defeat diabetes and other serious chronic diseases. Our purpose has remained the same for almost a 100 years, and today, it is more important than ever before.
Scientific breakthroughs are fundamental to progress, and we will
continue to innovate until we defeat diabetes. But our innovation to
improve lives must go hand in hand with access and
To provide support and relief to the most vulnerable patients in the
world is at the core of our social responsibility. It is essential to
our purpose to defeat diabetes.
The majority of people with diabetes live in low- and middle-income
countries.1 Access to reliable and affordable supplies of
insulin is a challenge for many. In fact, it is estimated that 50
million people lack access to insulin worldwide.2
Novo Nordisk has addressed this challenge since we introduced our Differential Pricing Policy for Least Developed Countries (LDCs) in 2001. Our continued commitment to having a low-cost insulin in our product portfolio and to producing and making human insulin available for years to come, is formulated in our Access to Insulin Commitment. Today, our Access to Insulin Commitment covers a total of 76 countries, home to a third of the world’s diabetes population1, as well as selected humanitarian organisations.
Our access to insulin commitment is one out of many initiatives in our social responsibility strategy, Defeat Diabetes.
The commitment builds on the following principles:
An estimated 2.9 million people were treated with insulin under this commitment in 2019, of which approximately 200,000 people were reached through sales to humanitarian organisations. In 2019, the average price the insulin was sold at under the commitment was USD 2.9 per vial, equalling 12 cents per patient per day.3 Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated additional 2.2 million people in 2019.
1. International Diabetes Federation. IDF Diabetes Atlas, 9 ed. Brussels, Belgium: International Diabetes Federation;2019.
2. ACCISS. Insulin Prices Profile. The Netherlands: Health Action International;2016.
3. Assuming average daily dose of 40 IU, as per WHO, Drug and
Therapeutic Committee - A Practical Guide, 2003, Annex 6.1.